MARINUS PHARMACEUTICALS INC (MRNS)
US56854Q2003 - Common Stock
Marinus Pharmaceuticals to Present at the RBC Capital Markets 2024 Global Healthcare Conference
Marinus Pharmaceuticals to Provide Business Update and Report First Quarter 2024 Financial Results on May 8, 2024
On Thursday, there are stocks with unusual volume. Let's take a look.
Which stocks have an unusual volume on Thursday?
On Wednesday, there are stocks with unusual volume. Let's take a look.
Let's have a look at the stocks with an unusual volume in today's session.
Unusual volume stocks in Tuesday's session
Unusual volume stocks in Tuesday's session
Noteworthy Monday Option Activity: MRNS, CVNA, PLL
Which stocks are experiencing notable movement on Monday?
Curious about what's happening in today's session? Check out the latest stock movements and price changes.
Biotech on a Budget: 7 Stocks Under $10 With Huge Potential
With the medical care industry always liable for negative surprises, you might as well go for big upside with under-$10 biotech stocks.
Which stocks are experiencing notable movement on Monday?
Which stocks are moving on Monday?
Why Are Stocks Up Today?
Stocks are up today and investors wondering what's behind that rally have come to the right place as we have the latest news for Monday!
DJT Stock Alert: Trump Media Plunges on Share Sale Panic
Trump Media & Technology stock is falling hard on Monday as investors react to a filing for a secondary offering of DJT shares.
Why Is Marinus Pharmaceuticals (MRNS) Stock Down 79% Today?
Marinus Pharmaceuticals stock is falling on Monday with heavy trading of MRNS shares after posting an update on a Phase 3 trial.
Gapping stocks in Monday's session
Today's session on Monday is marked by notable gaps in various stocks. Stay informed with the gap up and gap down stocks in today's session.
These stocks are moving in today's pre-market session
Before the opening bell on Monday, let's take a glimpse of the US markets and explore the top gainers and losers in today's pre-market session.
Marinus Pharmaceuticals Provides Update on the Phase 3 RAISE Trial and Reports Preliminary First Quarter 2024 Financial Results
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Notable Friday Option Activity: UAL, MRNS, ABNB
Commit To Buy Marinus Pharmaceuticals At $7, Earn 104.8% Annualized Using Options
Marinus Pharmaceuticals Comments on Patent Challenge by Ovid Therapeutics Inc. and Provides Update on Marinus’ Post Grant Review
Noteworthy Tuesday Option Activity: PYPL, MRNS, AVGO
Notable Thursday Option Activity: MRNS, PTEN, BKNG
Marinus Pharmaceuticals Enters Oversold Territory (MRNS)
Notable Wednesday Option Activity: MRNS, ABUS, ASO
MRNS Stock Earnings: Marinus Pharma Misses EPS, Misses Revenue for Q4 2023
MRNS stock results show that Marinus Pharma missed analyst estimates for earnings per share and missed on revenue for the fourth quarter of 2023.
MRNS Stock Earnings: Marinus Pharma Misses EPS, Misses Revenue for Q4 2023
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Marinus Pharma (NASDAQ:MRNS) just reported results for the fourth quarter of 20...
Marinus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
Marinus Pharmaceuticals to Present at Upcoming Investor Conferences
Marinus Pharmaceuticals to Provide Business Update and Report Fourth Quarter and Full Year 2023 Financial Results on March 5, 2024
